<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Sat, 10 Oct 2026 16:24:39 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[企業] Tevaの月1回注射の統合失調症薬Weltruzaを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110829&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110829&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 16:24:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110829&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肢帯筋ジストロフィーR2のスプリットインテイン利用遺伝子治療がマウスで有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110828&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110828&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 15:53:20 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110828&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 調節性T細胞（Treg）生み出す人工リンパ節が多発性硬化症（MS）マウスに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110827&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110827&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 14:53:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110827&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 神経内のαシヌクレイン凝集をマイクログリアが除去する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110826&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110826&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 12:50:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110826&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 生まれて間もないころの共生細菌が感染予防を担うカルプロテクチンを作らせる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110825&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110825&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 09:56:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110825&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 骨髄増殖性疾患のJAK2活性化V617F変異は赤血球を固くして大きな血栓を誘発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110824&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110824&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 08:50:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110824&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ミスマッチ修復欠損(dMMR)大腸癌切除患者へのRocheのTecentriq使用を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110823&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110823&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 10 Oct 2026 07:16:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110823&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Newron社の統合失調症薬Ph3試験差し止めに関する説明でFDAが4人の死亡に言及</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110822&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110822&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験 || 開発 / 臨床試験 / 中断</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 15:49:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110822&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ViatrisがPaciraを買って鎮痛薬2つを手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110821&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110821&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 14:56:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110821&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] argenx社のCD122阻害薬FB102のセリアック病Ph2試験が目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110820&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110820&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 14:14:49 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110820&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BMSのセレブロン標的薬Zenbexusが骨髄腫Ph3試験の無増悪生存改善目標も達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110819&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110819&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 12:13:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110819&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 優先審査権利をUltragenyxが2億1000万ドルで売却</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110818&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110818&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 11:29:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110818&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] argenx社の抗FcRn薬Vyvgart Hytruloのシェーグレン病Ph3試験が無益判定で中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110817&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110817&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 09:27:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110817&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] MimiVax社の癌ワクチンSurVaxMが膠芽腫Ph2b試験で生存を有意に改善できず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110816&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110816&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 08:17:34 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110816&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Merck &amp; Coの皮下注射Keytrudaの欧州の複数の国での販売禁止を裁判所が命じた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110815&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110815&amp;ref=rss</guid>
		<category>ビジネス / 世界の動き / ヨーロッパ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 09 Oct 2026 07:05:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110815&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] PfizerのHER2阻害薬Tukysaの乳癌治療の新たな用途を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110814&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110814&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 08 Oct 2026 16:54:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110814&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 皮膚描記症へのNovartisのBTK阻害経口薬Rhapsido使用を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110813&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110813&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 08 Oct 2026 16:10:22 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110813&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Cerevance社のGPR6阻害薬solengeprasのパーキンソン病Ph3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110812&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110812&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 08 Oct 2026 08:47:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110812&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 脳細胞を光で操る手段がノーベル賞を獲得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110811&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110811&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 08 Oct 2026 08:22:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110811&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Caribouが臨床試験段階の2つのCAR-T開発を打ち切り、社員をかなり減らす</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110810&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110810&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / リストラ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 08 Oct 2026 07:11:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110810&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ArriVent社のEGFR阻害薬firmonertinibの肺癌Ph3試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110809&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110809&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 16:36:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110809&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 先立つ治療がまだのDLBCL患者の無増悪生存がGenmab/AbbVieのEpkinlyで改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110808&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110808&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 16:07:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110808&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 遺伝性出血性毛細血管拡張症薬のRougeTx社が5800万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110807&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110807&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資 || ビジネス / 会社運営 / 開業</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 14:36:21 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110807&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 治療の甲斐なくHIVが見当たる患者にもGSKの定常2か月毎筋注Cabenuvaが有益</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110806&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110806&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 12:21:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110806&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Treg盛り上げ薬を開発するTRex Bio社が1億2500万ドルIPO調達計画</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110805&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110805&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / IPO</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 09:47:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110805&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Epicrispr社の顔面肩甲上腕型筋ジストロフィー薬のPh1/2試験成績が引き続き好調</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110804&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110804&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 07 Oct 2026 08:43:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110804&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 抗炎症/線維化のAlentis社の抗クローディン1抗体lixudebartにCSLが協力する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110803&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110803&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 16:29:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110803&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがGate社との提携に標的を1つ追加</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110802&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110802&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 15:12:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110802&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alector社の脳に届くグルコセレブロシダーゼ補充薬の権利をRocheが取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110801&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110801&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 12:59:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110801&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 50歳以上成人へのVaxcyte社の31価肺炎球菌ワクチンVAX-31のPh3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110800&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110800&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 11:53:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110800&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 塩野義製薬がIntraBio社を買って神経変性疾患薬Aqneursaを手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110799&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110799&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 10:09:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110799&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] アバメタピルとフラベソンの1回きり全身塗布がダニ寄生皮膚病の疥癬ブタに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110798&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110798&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 09:45:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110798&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 頭蓋骨髄からの単球が外傷性脳損傷後の神経炎症を促す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110797&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110797&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 08:52:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110797&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 多くを死なす菌血症を引き起こすMRSAが腎髄質内層にたむろすると判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110796&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110796&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 06 Oct 2026 08:30:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110796&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 米国第3代大統領Thomas Jeffersonが奴隷との間に子をもうけたことはかなり確実</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110795&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110795&amp;ref=rss</guid>
		<category>技術 / 診断 / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 16:46:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110795&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] アルツハイマー病患者の脳のもつれたタウが他のタウも同様にもつれさせる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110794&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110794&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 16:01:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110794&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] GATA2欠損症の遺伝子変異を効率よく安全に正すDSB不要プライム編集法開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110793&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110793&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 13:06:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110793&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 神経を胎盤膜で包むことで前立腺癌手術後の勃起を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110792&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110792&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 05 Oct 2026 10:58:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110792&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 1つの眉唾な小試験結果が小児の抗うつ薬プロザック使用を有益へと傾けた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110791&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110791&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / その他臨床試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 16:31:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110791&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 脳卒中がカルシウム伝達低下アストロサイトを発生させて神経膠腫を増やす</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110790&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110790&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 15:47:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110790&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 運動はmicroRNA-29豊富な細胞外小胞を介して軟骨細胞を若返らせる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110789&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110789&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 14:08:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110789&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Verastem社のRAF/MEK縛り付け薬+FAK阻害薬併用がKRAS G12C阻害薬を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110788&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110788&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 13:39:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110788&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 免疫や代謝へのプラスチック粒の大きさ毎の影響が判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110787&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110787&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 12:20:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110787&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaの異議でHansoh社のEGFR阻害薬Aumseqaの承認を欧州が取り消し</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110786&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110786&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 販売中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 10:35:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110786&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Pfizerの経口JAK阻害薬Litfuloの目標達成した白斑Ph3試験2つの結果詳細</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110785&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110785&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 09:57:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110785&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 米国の新会社Somniveraが臨床試験段階の睡眠障害薬の中国外権利を取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110784&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110784&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 09:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110784&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 体内でT細胞差し向け薬を作る自己免疫疾患治療をNovartisがAbogen社から取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110783&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110783&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 04 Oct 2026 08:33:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110783&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがFoghorn社とのSMARCA2標的薬提携打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110782&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110782&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 16:34:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110782&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 未治療の非肝硬変慢性HCV患者のsofosbuvir/velpatasvir投与8週間が12週間に比肩</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110781&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110781&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 14:07:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110781&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの経口GLP-1薬Foundayoの糖尿病治療の取り柄を示したPh3試験結果詳細</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110780&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110780&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 03 Oct 2026 12:20:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110780&amp;ref=rss</comments>
	</item>
</channel>
</rss>
